Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944 (MET-097i), which is an injectable GLP-1 receptor agonist. The trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Notably, patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks.

The study also confirmed a favorable safety and tolerability profile, consistent with the broader GLP-1 class, as gastrointestinal side effects were primarily mild to moderate. These results have reinforced Pfizer’s confidence in pursuing higher maintenance doses for its upcoming clinical trials. Detailed findings from the study are scheduled to be presented at the American Diabetes Association’s Scientific Sessions in June 2026.

Following its acquisition of Metsera, Pfizer is accelerating an expansive obesity development program that includes over 20 planned or ongoing studies. In 2026, the company expects to advance 10 Phase 3 trials for PF-08653944, including investigations into both weekly and monthly dosing regimens. This clinical push aims to address diverse patient needs and comorbidities through a pipeline that includes oral and injectable candidates.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.